CXCR3 and neoplasm: At the tumor site, N803 in combination with the vaccine alone or plus entinostat induced a significant Treg reduction and increased the activation of CD8+ T lymphocytes (TILs), including those expressing granzyme B. The synergistic effects of triple combination resulted in significant T-cell responses to vaccine and cascade antigens, including neoepitopes, the maximal infiltration of CD8+ T cells, as well as the enhanced transcription of genes associated with tumor inflammation and T-cell chemotaxis, including the CXCR3 ligands CXCL9, CXCL10, and CXCL11.